Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With Hepatitis C and Human Immunodeficiency Virus
Latest Information Update: 04 Aug 2023
Price :
$35 *
At a glance
- Drugs Ribavirin (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms CO13Hepavih
- 01 Aug 2023 Status changed from active, no longer recruiting to completed.
- 13 Aug 2020 Results (n=2641) comparing SVR rates as well as risk of all-cause death, liver-related and non-liver-related deaths, liver-related events, and non-liver-related cancers, between HIV/HCV co-infected and HCV mono-infected from two studies (NCT03324633 & NCT01953458), published in the Journal of Hepatology.
- 11 Mar 2020 Results (n=2641) from two clinical studies: ANRS CO22 HEPATHER and ANRS CO13 HEPAVIH assessing HIV Coinfection and Risk of Morbidity and Mortality in HCV patients were presented at the 27th Conference on Retroviruses and Opportunistic Infections